Oxolife raises €5M for its phase II Clinical Trial (infertility treatment)

Oxolife, a Barcelona, Spain-based company developing a drug with the potential to treat female infertility, announced the completion of a €5M ($5.6M) capital investment round.

The funding was led by Inveready Asset Management and the public body CDTI, alongside BStartup as well as HighStick2019, and private investors.

Oxolife, founded in 2013 by Agnès Arbat and Ignasi Canals,  is a small-size clinical-stage company focused on female fertility. The company is developing an innovative treatment (OXO-001) to enhance female fertility success through acting on peri/post implantatory process.  Additionally, OXO-001 restores ovulation. 

In early 2020 Oxolife raised 1.2 million euros from private investors through the Capital Cell platform.